Developing a Tool to Assess Red Blood Cell Clearance in Vivo Utilizing Pathogen-Reduced RBCs

TransfusionVolume 63, Issue S5 p. 271A-272A SUPPLEMENT ARTICLE P-TS-25 | Developing a Tool to Assess Red Blood Cell Clearance in Vivo Utilizing Pathogen-Reduced RBCs R. Benjamin, R. Benjamin Cerus Corporation, Concord, California, USASearch for more papers by this authorJ. Pitman, J. Pitman Cerus Corporation, Concord, California, USASearch for more papers by this authorK. Waldhaus, K. Waldhaus Cerus Corporation, Concord, California, USASearch for more papers by this authorJ. Cancelas, J. Cancelas Hoxworth Blood Center, Cincinnati, Ohio, USASearch for more papers by this authorN. Mufti, N. Mufti Cerus Corporation, Concord, CA, USA for the ReCePI InvestigatorsSearch for more papers by this authorP. Zerra, P. Zerra Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this authorR. Fasano, R. Fasano Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this authorM. Yee, M. Yee Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Department of Pediatrics, Division of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this author R. Benjamin, R. Benjamin Cerus Corporation, Concord, California, USASearch for more papers by this authorJ. Pitman, J. Pitman Cerus Corporation, Concord, California, USASearch for more papers by this authorK. Waldhaus, K. Waldhaus Cerus Corporation, Concord, California, USASearch for more papers by this authorJ. Cancelas, J. Cancelas Hoxworth Blood Center, Cincinnati, Ohio, USASearch for more papers by this authorN. Mufti, N. Mufti Cerus Corporation, Concord, CA, USA for the ReCePI InvestigatorsSearch for more papers by this authorP. Zerra, P. Zerra Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this authorR. Fasano, R. Fasano Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this authorM. Yee, M. Yee Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Georgia, USA; Department of Pediatrics, Division of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia, USASearch for more papers by this author First published: 12 October 2023 https://doi.org/10.1111/trf.362_17554Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume63, IssueS5October 2023Pages 271A-272A RelatedInformation